Pulmonary Mucormycosis with Brain (CNS) Involvement: When First-Line Treatment Has Not Achieved Complete Response
This protocol addresses pulmonary mucormycosis with central nervous system (brain) involvement in patients whose initial treatment course did not result in complete imaging response — covering the structured next step when the first-line approach falls short.
Clinical Scenario
The patient has pulmonary mucormycosis with confirmed or suspected central nervous system (brain) involvement — a severe complication that requires a defined antifungal management strategy and clear response benchmarks.
First-Line Treatment — Insufficient Response
The prior approach — early complete surgical debridement with clean margins plus immediate antifungal therapy with liposomal amphotericin B, followed where appropriate by a step-down to oral antifungal therapy (isavuconazole or posaconazole delayed-release tablets) — did not achieve the primary goal. At response assessment, imaging showed only stable disease or a partial response rather than complete response. This failure to meet the target triggers escalation to a salvage protocol.
Salvage Approach
A salvage strategy exists for this situation, centred on switching to a different antifungal drug class or intensifying the antifungal regimen. The clinical goal is resolution of signs and symptoms of infection and complete response on imaging. The full sequencing, agent selection, and combination options are available in the complete protocol.
References
- In CNS involvement, animal models and the above observations support use of liposomal amphotericin B at 10 mg/kg per day.
- Isavuconazole is strongly supported as salvage treatment.
- Posaconazole delayed release tablets or infusions are strongly supported for salvage treatment, and when available should be preferred over posaconazole oral suspension, which in turn is marginally supported for salvage treatment.
- In cases of primary treatment failure with isavuconazole or posaconazole, the guideline group supports recommendations for all three lipid-based amphotericin B formulations with strong to moderate strength.
- The guideline group strongly supports treatment until permanent reversal of immunosuppression and complete response on imaging, which might be difficult to determine because of scarring and postoperative changes.
View source ↗